Posted by Michael Wonder on 18 Mar 2020
ICER indefinitely postpones public meetings for sickle cell disease and cystic fibrosis; expands other assessment timelines up to three months
18 March 2020 - Updated schedules are intended to enable participating clinical experts and patient advocates to focus on caring for their communities during COVID-19 pandemic.
The ICER today announced several changes to its timelines for upcoming assessments. ICER’s review process involves significant engagement across a variety of external stakeholders — health care providers, life sciences companies, health insurers, and patient advocacy groups — the same types of organisations that are on the front line of preparing for and responding to the COVID-19 pandemic.
We are hopeful these expanded timeframes will enable all stakeholders to instead focus on meeting the needs of their patient communities during this national emergency.
